Last updated: February 22, 2026
What is the Drug Associated with NDC 70069-0013?
NDC 70069-0013 corresponds to Xyrem (sodium oxybate), used primarily to treat narcolepsy with cataplexy. It is a central nervous system depressant classified as a Schedule III controlled substance. Xyrem is marketed by Jazz Pharmaceuticals.
Market Size and Demand Dynamics
Prevalence and Market Penetration
- Narcolepsy affects approximately 0.03% to 0.05% of the U.S. population, equivalent to 90,000 to 150,000 patients.
- Approximately 70% of narcolepsy patients experience episodes of cataplexy.
- The target patient base for Xyrem is around 60,000-105,000 in the U.S., considering diagnosis rates and prescription patterns.
Market Growth Drivers
- Increased diagnosis rates.
- Expansion of clinical indications—off-label uses are limited but may grow.
- Mounting demand for effective narcolepsy treatments.
- Market entry barriers due to schedule classification and strict dispensing regulations.
Competitive Landscape
- Major competitors include Lunesta (suvorexant) and sodium oxybate alternatives approved for narcolepsy.
- Xyrem holds approximately 85%-90% market share in narcolepsy-specific treatments.
- The drug's high cost and controlled substance status influence prescribing patterns.
Regulatory Environment Impact
- FDA approval date: August 2002.
- Schedule III classification imposed additional distribution restrictions.
- Jazz Pharmaceuticals’ programs to improve awareness and diagnosis can influence market size.
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP): Approximately $30,000 per year per patient.
- Estimated average selling price (ASP): Slightly lower, around $28,000.
Cost Drivers
- Strict dispensing restrictions increase distribution costs.
- High manufacturing costs due to stabilization and controlled substance handling.
- Limited competition sustains high prices.
Price Projection Factors
- Market saturation: Near full penetration in narcolepsy with cataplexy, but potential for growth via expanded diagnosis.
- Regulatory pressures: Increased regulations or alternative treatments could lower prices.
- Patent and exclusivity status: No recent patent expirations, meaning continued exclusivity.
Forecast Outlook (Next 5 Years)
| Year |
Estimated Avg. Price per Patient |
Projected Market Size (Patients) |
Revenue Projection |
| 2023 |
$28,000 |
60,000 |
$1.68 billion |
| 2024 |
$27,500 |
65,000 |
$1.79 billion |
| 2025 |
$27,000 |
70,000 |
$1.89 billion |
| 2026 |
$26,500 |
75,000 |
$1.99 billion |
| 2027 |
$26,000 |
80,000 |
$2.08 billion |
Note: Prices are in nominal terms; inflation adjustments are not incorporated.
Sensitivity Analysis
- A 5% decline in prices may reduce revenue by $84 million annually.
- An increase in diagnosed patients by 10,000 could add approximately $250 million annually.
Market Entry Risks and Barriers
- Schedule III restrictions limit distribution channels.
- High manufacturing and compliance costs.
- Limited alternative treatments for narcolepsy with cataplexy.
- Potential for biosimilar or generic development remains low due to regulatory complexity.
Key Takeaways
- The narcolepsy treatment market, centered around Xyrem, is characterized by high demand, substantial pricing power, and regulatory barriers.
- Price projections suggest stable to slight decline, maintained by limited competition and high per-unit costs.
- Market growth primarily depends on diagnosis rate increases, with adjustments for regulatory shifts.
- Overall revenue from NDC 70069-0013 is expected to approach $2 billion annually within five years, given current market conditions.
FAQs
Q1: Is there a potential for biosimilar competition to impact pricing?
A: Biosimilar development is limited due to the complex manufacturing process and strict regulation. Significant biosimilar competition is unlikely in the near term.
Q2: How do regulatory changes affect future pricing?
A: Increased restrictions on distribution can raise costs, but they can also limit supply, potentially maintaining high prices. Deregulation or alternative treatment approvals could pressure prices downward.
Q3: Can off-label uses expand the market size?
A: Off-label use is minimal; regulatory restrictions limit off-label prescribing, maintaining the focus on narcolepsy with cataplexy.
Q4: How does patent status influence price stability?
A: As the original formulation has no recent patent expiration, patent exclusivity supports high prices until generic or alternative formulations are approved.
Q5: What is the impact of new therapies on Xyrem’s market share?
A: No major new therapies approved for narcolepsy with cataplexy are currently imminent; Xyrem’s market share remains dominant.
References
[1] Food and Drug Administration. (2002). Xyrem (sodium oxybate) approval announcement.
[2] IQVIA. (2022). U.S. prescription data for narcolepsy treatments.
[3] Jazz Pharmaceuticals. (2023). Xyrem sales and market reports.
